Brokerages expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to report $0.09 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Meridian Bioscience’s earnings. The lowest EPS estimate is $0.08 and the highest is $0.10. Meridian Bioscience reported earnings of $0.20 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 55%. The firm is scheduled to report its next quarterly earnings report on Thursday, November 14th.
According to Zacks, analysts expect that Meridian Bioscience will report full-year earnings of $0.64 per share for the current financial year, with EPS estimates ranging from $0.63 to $0.65. For the next fiscal year, analysts anticipate that the firm will post earnings of $0.51 per share, with EPS estimates ranging from $0.48 to $0.57. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Meridian Bioscience.
Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.06. The company had revenue of $48.40 million for the quarter, compared to the consensus estimate of $49.81 million. Meridian Bioscience had a return on equity of 17.82% and a net margin of 12.65%. The firm’s revenue was down 6.4% compared to the same quarter last year. During the same period last year, the business posted $0.18 earnings per share.
A number of research firms have recently issued reports on VIVO. Canaccord Genuity reiterated a “sell” rating and issued a $9.00 target price on shares of Meridian Bioscience in a research note on Wednesday, July 31st. Zacks Investment Research lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Friday, July 5th. BidaskClub raised shares of Meridian Bioscience from a “strong sell” rating to a “sell” rating in a report on Thursday, September 12th. Finally, ValuEngine lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Tuesday, August 13th. Four research analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. The company currently has an average rating of “Sell” and an average price target of $13.25.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in VIVO. Dimensional Fund Advisors LP grew its holdings in Meridian Bioscience by 0.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,901,563 shares of the company’s stock worth $33,011,000 after acquiring an additional 14,871 shares during the period. BNP Paribas Arbitrage SA grew its holdings in Meridian Bioscience by 298.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,688 shares of the company’s stock worth $171,000 after acquiring an additional 7,258 shares during the period. SG Americas Securities LLC acquired a new stake in Meridian Bioscience during the 1st quarter worth $246,000. Comerica Bank grew its holdings in Meridian Bioscience by 2.3% during the 1st quarter. Comerica Bank now owns 42,420 shares of the company’s stock worth $562,000 after acquiring an additional 937 shares during the period. Finally, Texas Permanent School Fund grew its holdings in Meridian Bioscience by 4.0% during the 1st quarter. Texas Permanent School Fund now owns 28,849 shares of the company’s stock worth $508,000 after acquiring an additional 1,101 shares during the period. 88.50% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:VIVO traded up $0.32 during trading on Friday, reaching $9.85. The stock had a trading volume of 12,051 shares, compared to its average volume of 208,144. Meridian Bioscience has a 52 week low of $8.96 and a 52 week high of $19.84. The business’s 50-day moving average price is $10.08 and its 200 day moving average price is $12.19. The company has a debt-to-equity ratio of 0.40, a current ratio of 6.93 and a quick ratio of 4.75. The stock has a market capitalization of $424.98 million, a PE ratio of 13.27 and a beta of 0.40.
About Meridian Bioscience
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.